EPCORITAMAB + R-CHOP CUTS THE RISK OF PROGRESSION OR DEATH BY 51%: BISPECIFICS ARE MOVING FROM “SALVAGE” TO FRONTLINE DLBCL
Key Development
AbbVie and Genmab have reported positive Phase 3 EPCORE DLBCL-2 topline results showing that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed higher-risk diffuse large B-cell lymphoma.
In the primary IPI 3–5 population, progression-free survival produced a hazard ratio of 0.49 (95% CI 0.35–0.69; p<0.0001). The global open-label Phase 3 trial was designed to randomize approximately 900 patients 2:1 to six cycles of epcoritamab plus R-CHOP followed by two cycles of epcoritamab, or six cycles of R-CHOP followed by two cycles of rituximab. The result came at the first planned efficacy interim analysis, after which the independent monitoring committee recommended unblinding the study.
The companies said safety was generally consistent with the known profiles of epcoritamab and R-CHOP. However, median PFS, absolute event rates, mature overall survival and detailed toxicity data have not yet been disclosed in the topline release. The combination remains investigational in newly diagnosed DLBCL.
Why It Matters
- Bispecifics are moving upstream. Epcoritamab already has regulatory approvals in relapsed/refractory lymphoma settings; frontline use would expose the franchise to a much larger patient population.
- A 51% relative risk reduction is substantial, but its clinical magnitude cannot be fully judged until absolute PFS data are available.
- R-CHOP is no longer the only frontline benchmark. Polatuzumab vedotin plus R-CHP has been FDA-approved since 2023 for untreated DLBCL/HGBL with IPI ≥2.
- Bispecifics offer different scalability from CAR-T: they are off-the-shelf and epcoritamab is administered subcutaneously.
- The class race is accelerating, with glofitamab- and odronextamab-based frontline programs also in Phase 3 development.
Healthcare Insight Analysis
Healthcare Insight believes EPCORE DLBCL-2 challenges a long-standing sequencing assumption in lymphoma:
T-cell engagement does not necessarily need to wait until chemotherapy has failed.
Epcoritamab is a CD3×CD20 bispecific antibody. It binds CD20 on malignant B cells while recruiting CD3-positive T cells, creating direct T-cell-mediated killing.
Adding that mechanism to first-line chemotherapy creates a new treatment architecture:
R-CHOP → R-CHOP + targeted immune recruitment.
That is strategically different from reserving bispecific antibodies for heavily pretreated disease.
But calling the regimen a new standard of care today would be premature.
The central competitive limitation is the comparator.
In POLARIX, pola-R-CHP reduced the risk of progression, relapse or death versus R-CHOP, with a hazard ratio of 0.73. The FDA subsequently approved pola-R-CHP for previously untreated DLBCL/HGBL patients with IPI scores of 2 or greater.
EPCORE DLBCL-2 therefore answers:
Does epcoritamab + R-CHOP beat R-CHOP?
It does not yet answer:
Does an epcoritamab-based strategy beat the strongest available frontline alternative?
That distinction will matter to guidelines, payers and hospital formularies.
The second issue is endpoint maturity.
DLBCL is potentially curable. That means overall survival, long-term remission, subsequent-treatment requirements and treatment burden matter considerably.
A strong PFS hazard ratio can be practice-changing, but its value depends on the absolute improvement, durability after fixed-duration therapy, and whether the additional bispecific burden is justified by better outcomes.
Cytokine release syndrome is particularly relevant operationally. Earlier epcoritamab experience showed CRS is often manageable and predominantly low grade, but frontline use would shift these monitoring requirements into a much larger patient population.
Commercially, the readout is important because it advances epcoritamab from a specialty late-line product toward a potential franchise backbone.
AbbVie and Genmab originally entered their broad bispecific oncology partnership in 2020, with AbbVie paying $750 million upfront and Genmab eligible for up to $3.15 billion in additional milestones across the collaboration.
Moving Epkinly into first-line DLBCL could materially raise its commercial ceiling.
But the strategic prize is broader than volume.
If an off-the-shelf bispecific can be integrated safely into curative-intent frontline therapy, the entire treatment hierarchy between chemotherapy, antibodies, bispecifics and CAR-T could begin to move.
Market Implications
AbbVie/Genmab: the Phase 3 result materially de-risks Epkinly’s expansion into earlier disease.
Roche: pola-R-CHP becomes an increasingly important practical benchmark rather than R-CHOP alone.
Bispecific competitors: success raises the bar for glofitamab and odronextamab frontline programs.
Hospitals: broader first-line use would require scalable step-up dosing, CRS monitoring and outpatient/inpatient coordination.
ANALYTICAL MATRIX
| Dimension | Current Signal | Strategic Meaning | Remaining Question |
| PFS | HR 0.49 | Strong relative benefit | Absolute benefit? |
| Setting | Newly diagnosed | Much larger population | Better than pola-R-CHP? |
| Modality | CD3×CD20 bispecific | Off-the-shelf T-cell engagement | CRS/logistics |
| Duration | Fixed-duration | Avoids indefinite therapy | Durability after stopping |
| Commercial | Frontline expansion | Major franchise upside | Guideline/payer adoption |
EPCORE DLBCL-2 may represent an important milestone for the entire bispecific class: T-cell engagement is no longer confined to patients who have exhausted several previous therapies; it may move directly into curative-intent first-line treatment.
But the next benchmark is harder than R-CHOP.
To redefine frontline DLBCL, epcoritamab must ultimately show not only that adding a bispecific improves chemotherapy, but that the total regimen delivers enough additional clinical value to outperform a frontline landscape that has already begun moving beyond R-CHOP itself.